Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
PMGC Holdings ( (ELAB) ) just unveiled an update.
On December 17, 2025, NorthStrive Biosciences, a subsidiary of PMGC Holdings, announced it had initiated Phase III of its AI Development Program with Yuva Biosciences to move AI-identified small-molecule candidates for obesity and related metabolic conditions into experimental validation. The program, which builds on Phase II work using YuvaBio’s MitoNova mitochondrial-focused AI platform, will focus on generating biological data, including cytotoxicity screening and ANT1 gene expression testing, to prioritize compounds that may support mitochondrial health and muscle preservation in patients on GLP-1 therapies over a planned six-to-nine-week Phase III timeline, potentially strengthening PMGC’s position in obesity-related therapeutics and AI-driven drug discovery.
Spark’s Take on ELAB Stock
According to Spark, TipRanks’ AI Analyst, ELAB is a Underperform.
ELEVAI Labs Inc. is rated poorly due to major financial weaknesses, including negative revenue and cash flow issues, which are exacerbated by adverse technical indicators. The lack of favorable valuation metrics further weighs down the stock’s score. The absence of applicable corporate events means no positive catalysts are present to offset these challenges.
To see Spark’s full report on ELAB stock, click here.
More about PMGC Holdings
PMGC Holdings Inc. is a diversified holding company that grows its portfolio through strategic acquisitions, investments and development across multiple industries, currently owning four wholly owned subsidiaries: NorthStrive Biosciences Inc., PMGC Capital LLC, Pacific Sun Packaging Inc. and AGA Precision Systems LLC. NorthStrive Biosciences, a PMGC subsidiary, is a biopharmaceutical business focused on developing and acquiring advanced aesthetic medicines, with a lead asset, EL-22, that uses an engineered probiotic approach to help preserve muscle in patients undergoing obesity treatments, including GLP-1 receptor agonists.
Average Trading Volume: 702,830
Technical Sentiment Signal: Sell
Current Market Cap: $1.68M
See more insights into ELAB stock on TipRanks’ Stock Analysis page.